How Investors May Respond To Sandoz Group (SWX:SDZ) Winning EU Approval For Ondibta Biosimilar Insulin

In January 2026, Sandoz confirmed that the European Commission had granted marketing authorization for Ondibta®, a biosimilar insulin glargine pre-filled pen for patients with diabetes aged two and above, matching Lantus® SoloStar® in safety, quality and efficacy. This approval, under Sandoz’s commercialization agreement with Gan & Lee, reinforces its biosimilar footprint in diabetes care and supports broader access to insulin across Europe. We will now examine how this European Commission approval for Ondibta®, and its potential to expand insulin access, shapes Sandoz’s investment narrative. Explore 23 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.What Is Sandoz Group's Investment Narrative?To own Sandoz, you really need to believe in its ability to turn a large, still-forming biosimilar pipeline into durable, improving economics, despite a rich valuation and a relatively new board. The European Commission approval for Ondibta® fits neatly into that story: it reinforces Sandoz’s role in broadening access to biologics and adds another future revenue stream in diabetes, although the launch timing (not expected before early 2027) means it is unlikely to change the near term picture in a material way. Short term, the more immediate catalysts remain the ramp-up of recent denosumab and aflibercept biosimilar launches, plus progress on trastuzumab approvals, set against risks such as high earnings multiples, modest current profitability and interest cover, and ongoing execution demands from a wide external development network. However, one key financial pressure point here is easy to miss at first glance. Sandoz Group's shares have been on the rise but are still potentially undervalued by 43%. Find out what it's worth.Exploring Other PerspectivesSWX:SDZ 1-Year Stock Price Chart Four Simply Wall St Community fair value views for Sandoz span from about CHF40 to over CHF109, underlining how far apart individual expectations can sit. Set against this broad range, the Ondibta® approval adds another longer term growth option, but also increases execution risk across an already busy biosimilar launch schedule, something readers may want to weigh carefully when comparing these differing assessments.Explore 4 other fair value estimates on Sandoz Group - why the stock might be worth as much as 75% more than the current price!Build Your Own Sandoz Group NarrativeDisagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.A great starting point for your Sandoz Group research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.Our free Sandoz Group research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Sandoz Group's overall financial health at a glance.Interested In Other Possibilities?Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:AI is about to change healthcare. These 110 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.Find companies with promising cash flow potential yet trading below their fair value.These 10 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.